Cancer development is a dynamic process during which the successive accumulation of mutations results in cells with increasingly malignant characteristics. Here, we show the clonal evolution pattern in myelodysplastic syndrome (MDS) patients receiving supportive care, with or without lenalidomide (follow-up 2.5-11 years). Whole-exome and targeted deep sequencing at multiple time points during the disease course reveals that both linear and branched evolutionary patterns occur with and without disease-modifying treatment. The application of disease-modifying therapy may create an evolutionary bottleneck after which more complex MDS, but also unrelated clones of haematopoietic cells, may emerge. In addition, subclones that acquired an additional mutation associated with treatment resistance (TP53) or disease progression (NRAS, KRAS) may be detected months before clinical changes become apparent. Monitoring the genetic landscape during the disease may help to guide treatment decisions.

Department of Haematology Centro Hospitalar de São João and Faculdade de Medicina da Universidade do Porto Alameda Professor Hernâni Monteiro Porto 4200 319 Portugal

Department of Hematology Radboud University Medical Center Geert Grooteplein Zuid 8 6525 GA Nijmegen The Netherlands

Department of Hematology University Medical Centre Groningen PO Box 30001 9700 RB Groningen The Netherlands

Department of Human Genetics Radboud University Medical Center Geert Grooteplein Zuid 8 6525 GA Nijmegen The Netherlands

Department of Pathology and Tumor Biology Graduate School of Medicine Kyoto University Yoshida Konoe cho Sakyo ku Kyoto shi Kyoto 606 8501 Japan

Department of Tumor Immunology Radboud University Medical Center Radboud Institute for Molecular Life Sciences Geert Grooteplein Zuid 8 6525 GA Nijmegen The Netherlands

Human Genome Center Institute of Medical Science The University of Tokyo 4 6 1 Shirokanedai Minato ku Tokyo 108 8639 Japan

Institute of Hematology and Blood Transfusion U Nemocnice 1 128 20 Prague 2 Czech Republic

Institute of Medical Informatics University of Münster Albert Schweitzer Campus 1 48149 Münster Germany

Laboratory of Hematology Radboud University Medical Center Geert Grooteplein Zuid 8 6525 GA Nijmegen The Netherlands

Zobrazit více v PubMed

Bejar R. et al.. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496–2506 (2011). PubMed PMC

Papaemmanuil E. et al.. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627 quiz 3699 (2013). PubMed PMC

Haferlach T. et al.. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014). PubMed PMC

Welch J. S. et al.. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012). PubMed PMC

Walter M. J. et al.. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090–1098 (2012). PubMed PMC

Klco J. M. et al.. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379–392 (2014). PubMed PMC

Grove C. S. & Vassiliou G. S. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis. Model. Mech. 7, 941–951 (2014). PubMed PMC

McGranahan N. & Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15–26 (2015). PubMed

Lin T. L. et al.. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica 99, 28–36 (2014). PubMed PMC

Mian S. A. et al.. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat. Commun. 6, 10004 (2015). PubMed PMC

Chesnais V. et al.. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood 127, 749–760 (2016). PubMed PMC

Walter M. J. et al.. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27, 1275–1282 (2013). PubMed PMC

Woll P. S. et al.. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25, 794–808 (2014). PubMed

Mossner M. et al.. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood 128, 1246–1259 (2016). PubMed

Jadersten M. et al.. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J. Clin. Oncol. 29, 1971–1979 (2011). PubMed

Caye A. et al.. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat. Genet. 47, 1334–1340 (2015). PubMed

Meggendorfer M. et al.. Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia. Haematologica 100, e487–e490 (2015). PubMed PMC

Takahashi K. et al.. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27, 2081–2083 (2013). PubMed

Badar T. et al.. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk. Res. 39, 1367–1374 (2015). PubMed PMC

Dunna N. R. et al.. NRAS mutations in de novo acute leukemia: prevalence and clinical significance. Indian J. Biochem. Biophys. 51, 207–210 (2014). PubMed

Singh H., Longo D. L. & Chabner B. A. Improving prospects for targeting RAS. J. Clin. Oncol. 33, 3650–3659 (2015). PubMed

Kronke J. et al.. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature 523, 183–188 (2015). PubMed PMC

Saft L. et al.. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica 99, 1041–1049 (2014). PubMed PMC

Smith A. E. et al.. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. Lancet Haematol. 2, e212–e221 (2015). PubMed

Heuser M. et al.. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia 29, 1942–1945 (2015). PubMed

Bello E. et al.. CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). Br. J. Haematol. 171, 153–294 (2015). PubMed PMC

Wong T. N. et al.. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 127, 893–897 (2016). PubMed PMC

Xie M. et al.. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014). PubMed PMC

Jaiswal S. et al.. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014). PubMed PMC

Genovese G. et al.. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014). PubMed PMC

Merlevede J. et al.. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat. Commun. 7, 10767 (2016). PubMed PMC

Mohamedali A. M. et al.. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia 29, 1928–1938 (2015). PubMed

Jabbour E. & Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am. J. Hematol. 91, 252–265 (2016). PubMed

Shaffer L. G., McGowan-Jordan J. & Schmid M. ISCN 2013: an International System for Human Cytogenetic Nomenclature Karger (2013).

Pang W. W. et al.. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc. Natl Acad. Sci. USA 110, 3011–3016 (2013). PubMed PMC

Shlush L. I. et al.. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014). PubMed PMC

Yoshida K. et al.. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69 (2011). PubMed

Simons A. et al.. Microarray-based genomic profiling as a diagnostic tool in acute lymphoblastic leukemia. Genes Chromosomes Cancer 50, 969–981 (2011). PubMed

Schoumans J. et al.. Guidelines for genomic array analysis in acquired haematological neoplastic disorders. Genes Chromosomes Cancer 55, 480–491 (2016). PubMed

Heinrichs S., Li C. & Look A. T. SNP array analysis in hematologic malignancies: avoiding false discoveries. Blood 115, 4157–4161 (2010). PubMed PMC

Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013). PubMed PMC

Cazzola M. & Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 123, 3714–3719 (2014). PubMed

Makishima H. et al.. Somatic SETBP1 mutations in myeloid malignancies. Nat. Genet. 45, 942–946 (2013). PubMed PMC

Micol J. B. et al.. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood 124, 1445–1449 (2014). PubMed PMC

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes